Webinar: Optimising viral vector manufacturing with CDMO expertise and innovation

News: OXB honoured at 2025 CDMO Leadership Awards Europe in ‘Cell & Gene Therapy’ category

Home – CDMO Solutions | Viral Vectors | Lentivirus

30 years of lentiviral vector manufacturing

As a pioneer in lentiviral vector technology, OXB brings three decades of proven experience to the development and manufacturing of lentiviral vectors for cell and gene therapies. Now a global CDMO, we support partners from early development through to commercialisation.

With over 340 GMP batches successfully manufactured, and 25 regulatory submissions supported, OXB offers deep regulatory, process, and analytical expertise to accelerate advanced therapy programmes from discovery to market.

OXB’s lentiviral vector track record

0+

GMP batches successfully released

0

Successful regulatory submissions

0

months

To GMP release

0E+

12 TU

At 200L scale

0%

Analytical assays performed in-house

0+

Patients’ doses

LentiVector™ platform

Taking novel therapies from discovery to commercialisation

OXB’s LentiVector™ platform offers a fully integrated and optimised suite of technologies and processes for the scalable production of high-quality lentiviral vectors. Designed to meet the complex demands of the cell and gene therapy market, the platform encompasses vector design, upstream and downstream processing, analytics, and fill/finish services, all aligned to deliver robust, reproducible GMP manufacturing.

The platform offers 3rd generation and 4th generation lentiviral vector systems, including proprietary innovations; 2KO genome™, SupA-LTR™, MaxPax™, and the TRiP System™, that together can enhance vector potency, productivity, quality, and safety.

With the LentiVector™ platform, clients benefit from high-yield, high-volume GMP manufacturing, scalable from early clinical to commercial supply, supported by deep regulatory expertise across global markets.

Explore the LentiVector™ platform

Our platform technologies:

3rd and 4th generation vector systems:
3rd generation plasmid system plus 4th generation TetraVectaTM system add-ons for solving complex issues.
3<sup>rd</sup> and 4<sup>th</sup> generation vector systems:
Optional packaging or producer LentiStableTM cell lines:
the scaleable solution for high-demand LV therapies.
Optional packaging or producer LentiStable<sup>TM</sup> cell lines:
Suspension & perfusion production processes:
optimised and scalable process with improved productivity using OXB enhancing technologies.
Suspension & perfusion production processes:
Purification, concentration & formulation:
robust and scalable process using the latest downstream technologies.
Purification, concentration & formulation:

Why choose OXB as your LV CDMO?

Taking novel therapies from discovery to commercialisation

OXB-Viral-vectors-AAV-2-800x800px

Access innovative technology and unmatched expertise

With decades of leadership in lentiviral vector production, OXB gives clients access to some of the industry’s most experienced scientific minds. Our commitment to continuous innovation ensures clients benefit from the latest advancements in 
viral vector manufacturing to deliver best in class cell and gene therapies.

OXB-CDMO-Regulatory-support-1-800x800px

Receive comprehensive regulatory support through to commercialisation

OXB provides end-to-end regulatory support, guiding clients from preclinical development through to commercial launch. We have successfully supported multiple IND and MAA submissions, and maintain a Drug Master File (DMF) with the FDA, reinforcing our credibility as a trusted global CDMO partner.

OXB-CDMO-GMP-manufacturing-1-800x800px

Leverage local manufacturing with a global footprint

With harmonised lentiviral vector manufacturing processes across our UK, US, and European facilities, OXB enables efficient, scalable production from 50L to 1000L, close to your clinical or commercial markets. Our global footprint ensures flexibility, consistency, and speed—wherever you are.

Ways to work with us

There are multiple ways in which pharma, biotechs and start-ups work with us, depending on development phase, scale, and individual IP requirements.

White-hexagon

Platform project

For clients that are pre-clinical or early-clinical that wish to reach GMP at an accelerated rate with a proven process.

White-hexagon

Custom solution

For clients that are pre-clinical or early-clinical that require flexibility in the manufacture of their drug candidate.

White-hexagon

Tech-transfer

For clients in phase I, II, or III that need to transfer their manufacture to a CDMO for scale and/or long-term manufacture.

Flex-box-Ways-to-work-with-us-1-840x480px
Flex-box-Ways-to-work-with-us-2-840x480px
Flex-box-Ways-to-work-with-us-3-840x480px

Frequently asked questions

Can OXB support both clinical and commercial supply of lentiviral vectors?
What analytical assays are used to characterize lentiviral products?
How does OXB support tech transfer for lentiviral vector programs?
What experience does OXB have with approved lentiviral therapies?

Looking for something specific? – let's discuss a custom project

For pre-clinical clients that would like to co-develop a highly specific process, our custom project offering allows you to access OXB’s technology in combination with others to create a truly unique solution to meet your individual requirements.

OXB-Looking-for-something-specific-832x480px